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Abstract
Background: When a sponsor funds a study of two competing drugs in a head-to-head comparison, the results and
conclusions are likely to favor the sponsor’s drug. Thiazolidinediones, oral medications used for the treatment of type 2
diabetes, are one of the most costly choices of oral anti-diabetic medications, yet they do not demonstrate clinically relevant
differences in achieving lower glycosylated hemoglobin levels compared to other oral antidiabetic drugs. Our aim is to
examine associations between research funding source, study design characteristics aimed at reducing bias, and other
factors with the results and conclusions of randomized controlled trials (RCTs) of thiazolidinediones compared to other oral
hypoglycemic agents.
Methods and Findings: This is a cross-sectional study of 61 published RCTs comparing a thiazolidinedione (glitazone) to
another anti-diabetic drug or placebo for treatment of type 2 diabetes. Data on study design characteristics, funding source,
author’s financial ties, results for primary outcomes, and author conclusions were extracted. Univariate logistic regression
identified associations between independent variables and results and conclusions that favored the glitazone. Of the RCTs,
59% (36/61) were funded by industry, 39% (24/61) did not disclose any funding. Common study design weaknesses
included inadequate blinding and lack of concealment of allocation. Trials that reported favorable glycemic control results
for the glitazone were more likely to have adequate blinding (OR (95% CI) = 5.42 (1.46, 21.19), p = 0.008) and have a
corresponding author with financial ties to the glitazone manufacturer (OR (95% CI) = 4.12 (1.05, 19.53); p = 0.04). Trials with
conclusions favoring the glitazone were less likely to be funded by a comparator drug company than a glitazone company
(OR (95% CI) = 0.026 (0, 0.40), p = 0.003) and less likely to be published in journals with higher impact factors (OR (95% CI)
= 0.79 (0.62, 0.97), p = 0.011). One limitation of our study is that we categorized studies as funded by industry based on each
article’s disclosure which could underestimate the number of industry sponsored studies and personal ties of investigators.
Additionally, our study did not include any head-to-head comparisons of one glitazone to another.
Conclusions: Published RCT comparisons of glitazones with other anti-diabetic drugs or placebo are predominantly industry
supported and this support, as well as the financial ties of study authors, appears to be associated with favorable findings.
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Introduction
Randomized controlled trials are often used to compare the
efficacy of two drugs. However, factors such as trial design and
subsequent execution, data analysis, and data presentation can
introduce bias and discrepancies in reported outcomes [1,2]. In
addition, publication bias occurs through publication of either
partial results or statistically significant information only, and is
difficult to measure [3,4].
Pharmaceutical company sponsored trials comparing the
sponsor’s drug to a placebo are more likely to report favorable
conclusions for the sponsor’s drug [5–8]. However, many previous
studies of bias have focused on single study design features and not
on the aggregated causes of bias that result in favorable results and
conclusions [9–11]. For example, many studies of association of
funding source and favorable outcomes have not explored the
effect of comparator drug selection and dosing in head -to -head
drug comparisons. Bias introduced by inadequate randomization,
concealment of allocation, blinding, or comparator drug choice
and dosing, for example, could also be associated with publication
of statistically significant results [8,12]. Heres et al. [2] and Bero et
al.[13] have shown that when a sponsor funds a study of two
competing drugs in a head-to-head comparison, the results and
conclusions are more likely to favor the sponsor’s drug.
Thiazolidinediones, oral medications used for the treatment of
type 2 diabetes, provide an interesting class of drugs to examine
sources of bias in drug comparison trials. Type 2 diabetes
incidence and prevalence is rapidly increasing globally and when
uncontrolled can result in many costly macro- and microvascular
comorbidities [14,15]. Thiazolidinediones have been cited as one
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of the most costly choices of oral anti-diabetic medications,
providing a lower magnitude of glycemic control than several
other therapeutic drug classes used for type 2 diabetes [14,16,17].
Recent systematic reviews found that these agents did not
demonstrate clinically relevant differences in their ability to lower
glycosylated hemoglobin levels compared to other oral antidiabetic
drugs [18,19]. Thiazolidinediones also have the potential to affect
lipid profiles, a common metabolic co-morbidity with diabetes
[20–22]. Specifically, pioglitazone can improve, while rosiglita-
zone can negatively affect lipid values. Although glitazones are
often used as combination therapy when glycemic control has not
been achieved with at least one other oral agent, they are also
approved for monotherapy [17,20–22]. An alternative choice of
third agent for glycemic control is often insulin, however; many
patients prefer oral agents and to avoid initiating insulin therapy as
long as possible [17,22]. We chose to focus on thiazolidinedione
trials for two reasons: 1. There are oral agents from the biguanide
and sulfonylurea classes that provide equivalent glycemic control
and are available as generic drugs [14,16,18,19]and 2. Most
insulin therapy offers a less costly alternative to the addition of a
thiazolidinedione as a third oral agent to provide glycemic control
[14,17,22].
This cross-sectional study examines the results and conclusions
published in randomized controlled trials (RCTs) of glitazone-
placebo comparisons and glitazone-alternative anti-diabetic drug
comparisons, and their associations with trial funding source, study
design features aimed at reducing bias, and other factors. We
hypothesized that results and conclusions of trials are more likely
to favor the study sponsor’s drug, and that design features such as
randomization, blinding, and analysis technique, as well as
author’s financial ties, are associated with significant results
favoring the study sponsor’s drug.
Methods
Search strategy
We searched PubMed and the Cochrane Library to identify
randomized controlled trials published between January 1996 and
December 2006 using the MeSH terms and drug names
‘‘pioglitazone and diabetes’’ and ‘‘rosiglitazone and diabetes.’’
with limits of ‘clinical trial, ‘humans’, ‘all adult: 19+ years’ and
‘English’. The search was limited to these dates because the first
published thiazolidinedione trials [23] of troglitazone, which was
subsequently removed from the market in 2000 and consequently
is not included in our study, started appearing around 1996. The
first trials on rosiglitazone and pioglitazone were published in
1999. Reference lists of all potentially relevant articles identified
through the PubMed search and a recent meta-analysis [24] and
systematic review [18] were also reviewed.
Inclusion and Exclusion Criteria
All abstracts were reviewed and studies were selected for
inclusion based on the following criteria: 1) type 2 diabetes
mellitus diagnosis; 2) adult study population .18 years of age; 3)
glycemic control and/or lipid level measures as outcomes; 4)
original trial data were presented; 5) pioglitazone or rosiglitazone
were compared to either placebo or another anti-diabetic drug
or combination from a different drug class; and 6) one study arm
did not contain a glitazone. Because we were interested in
looking at clinical trials examining the efficacy of pioglitazone or
rosiglitazone as compared to other therapeutic classes of
antidiabetic drugs or placebo, we also excluded head-to-head
studies of the glitazones by requiring that inclusion criteria 5 and
6 were met.
Articles were excluded based on the following criteria: 1)
diagnoses other than type 2 diabetes mellitus including a pre-
diabetes diagnosis such as impaired glucose tolerance, polycystic
ovary syndrome, HIV lipodystrophy, prior gestational diabetes
without current DM diagnosis, 2) pharmacokinetics or pharma-
codynamics studies; 3) studies that did not include original trial
data such as comments and letters to the editor, reviews, study
design and rationale only, re-analyses of previous trial data; 3)
trials without primary outcomes focused on improved glycemic
control measures and/or lipid level measures such as reduced
carotid intima media thickness; 4) trials with troglitazone, as it has
been removed from the market due to hepatic toxicity and is not
relevant to current drug therapy selection; 5) trials in which dosing
ranges were compared without a placebo arm; 6) comparisons of
either pioglitazone or rosiglitazone to non-drug interventions such
as diet, exercise, improved memory and increased energy level; 7)
studies in which a glitazone was present in all study arms; 8) trials
of less than 12 week duration as shorter durations do not allow
accurate assessment of changes in glycosylated hemoglobin
(HgbA1C) value, a key measure of changes in glycemic control
and 9) in-vitro and mechanistic studies. Discrepancies about
inclusion were discussed by both authors until consensus was
reached. A chance of bias in selection is that neither coder was
blinded to study results or conclusions.
Although no exact duplicate publications were found, we
identified 22 publications that either re-analyzed data from a
combination of trials, reported on different outcomes from the
same trial or were sub-analyses of data sets. The publication with
the earliest publication date was used, unless a later publication
included more data of interest; for example inclusion of both
glycemic control and lipid level measures in a single publication.
Data extraction
The first author (G.B.R.) extracted all data from each article. All
of the coding was discussed with a second coder (L.A.B.) and
results were adjudicated to reach agreement. As before, there is
some chance that bias was introduced as neither coder was blinded
to study results or conclusions.
We extracted data on the following publication characteristics
shown to be independently related to favorable results or
conclusions of some drug studies [2,5,7,10,25,26]. The association
of these characteristics with the results and conclusions of
thiazolidinedione trials is uncertain.
Journal characteristics
Peer Review Status. Every article was classified as peer
reviewed, non- peer reviewed or unknown by using information
provided on the journal’s website regarding the publication review
process. Articles were classified as peer reviewed if the website
stated that the journal had a peer review process or that submitted
manuscripts were evaluated by at least one expert in the field;
otherwise the publication was classified as non-peer reviewed. If no
information could be found on a particular journal, we classified
peer review status as unknown.
Impact Factor. Impact factors for journals were obtained
from the Institute for Scientific Information, 2005 data [27].
Study characteristics
Comparison Groups. Each article was classified as either a
drug vs. placebo-control or drug-drug comparison trial. Drug-drug
comparison trials which explicitly stated that they were non-
inferiority designs were noted. The ‘‘test’’ drug was defined as the
glitazone in every trial.
Bias Thiazolidinedione Trials
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Sample Size. We recorded the number of patients included
in the analysis of each trial.
Study design characteristics aimed at reducing bias
We evaluated the following study design attributes aimed at
reducing bias [28]:
Randomization and concealment of allocation. We
classified each trial as having adequate (score of 1) or inadequate
(score of 0) randomization and concealment of allocation based on
the description of the method of randomization. Specifically, the
mere mention of randomization in the methods section was
insufficient to receive an adequate randomization score. A detailed
description of the way concealment of allocation and randomization
were achieved was necessary to receive an adequate score. For
example, if the methods described central randomization by a third
party or the use of sealed, opaque envelopes, the trial received a score
of adequate. If there was no description or mention of
randomization, the paper received an inadequate score.
Blinding. We classified each trial as having adequate (score of
1) or inadequate (score of 0) blinding of subjects, study
investigators, study personnel administering therapy or assessing
trial outcomes, and statisticians. A description of blinding had to
be given to receive an adequate score; otherwise this attribute was
coded as inadequate.
Intention-to-treat analysis. We classified each trial as
having adequate (score of 1) or inadequate (score of 0) intention-
to-treat analysis. If the paper stated that it used an intention-to–
treat analysis , it received an adequate score as it was often unclear
whether or not exclusions actually occurred. Thus, we likely
overestimated the occurrence of true intention-to-treat analysis.
Follow-up. We classified each trial as having adequate (score
of 1) or inadequate (score of 0) follow-up. Follow-up of $75% was
required to receive an adequate score.
Appropriate dosing range. We classified each trial as
having adequate or inadequate drug dosages using standard
dosing ranges [17,22].
Outcome Measures
Coding of Study Results. We examined glycemic control
and lipid profile outcomes measures. For glycemic control results
we extracted data on glycosylated hemoglobin (HgbA1C)
percentages and fasting (FPG/FBG) and/or post-prandial
plasma or blood (PPG/PBG) glucose levels. For lipid level
results we used total cholesterol (TC), low density cholesterol
(LDL-c), high density cholesterol (HDL-c), and triglyceride (TG)
levels.
For each article, results reported for each outcome of interest
were categorized as 1) favorable to the ‘‘test’’ drug (glitazone) if it
was statistically significant (p,0.05 or confidence intervals that
excluded no difference) and in the direction of the glitazone being
more efficacious, 2) no difference / about equal if it was
statistically insignificant, or 3) unfavorable if the result was
statistically significant in the direction of the placebo or
comparator drug being more efficacious. We coded results from
non-inferiority studies as favorable when results were equivalent or
better between the glitazone and its comparison drug. Results for
primary outcomes were coded separately for glycemic control
results and lipid level results. These were then classified
independently as favorable for glycemic control if the overall
glycemic control results favored the glitazone and as favorable for
lipid level profile if the overall lipid level results favored the
glitazone. For analysis, we categorized results as favorable or not,
combining the about equal/ no difference and unfavorable
categories.
Coding of Study Conclusions. Conclusions, reported in the
discussion section in published papers, were abstracted and coded.
Conclusions were classified as 1) favorable, if the glitazone therapy
was preferred over the placebo or comparator drug therapy, 2) no
difference / about equal, if there was no preference stated for the
glitazone drug therapy over the placebo or comparator drug
therapies or 3) unfavorable, if the placebo or comparator drug
therapies were preferred over the glitazone therapy. Non-
inferiority studies were coded as favorable if the glitazone
therapy was deemed equivalent to or better than the comparator
therapies, as the goal of these trials is to show that drug therapies
are equivalent and we are not assessing the size of the effect. When
an article did not clearly state a preference for one therapy over
another it was coded as no difference / about equal. For analysis,
we categorized conclusions as favorable or not, combining the
about equal/ no difference and unfavorable categories.
Author characteristics
Institutional Affiliation. Corresponding author affiliation
was obtained from the article and classified as 1) ‘‘test’’ drug
company (glitazone company), 2) any other industry, 3) academic
or hospital or 4) unknown.
Funding information
Funding source. Funding source(s) of published studies were
categorized as 1) ‘‘test’’ drug (glitazone), 2) any other industry
funding, 3) drug company plus other funding source(s) (mixed
funding sources), 4) all other funding (no drug company funding),
or 5) no funding disclosure. All categories that applied were coded,
so studies that received funding from a glitazone manufacturer as
well as other industry funding could be differentiated from studies
that received funding from a single drug company. Due to our
sample size, studies that received any funding from the ‘‘test’’ drug
company (N=4) were ultimately combined with those funded
exclusively by the ‘‘test’’ drug company (N= 26).
Financial Ties. We extracted and coded data about the
disclosed financial ties of the first and corresponding author as 1)
any financial ties disclosed with the sponsor of the study, 2) any
financial ties disclosed with any other drug company, 3) ‘‘test’’
drug (glitazone) company employee, 4) any other drug company
employee and 5) no financial tie disclosure. All categories that
applied were coded.
Statistical Analysis
We report frequencies of the different characteristics of each
article. For characteristics with sufficient variability, we determine
whether particular characteristics were associated with favorable
results or conclusions. We used univariate, exact logistic regression
to identify associations between explanatory variables and
favorable results and conclusions. Odds ratios (ORs), which report
the ratio between the odds of having an event or outcome and the
odds of not having an event or outcome, were estimated. Our
intention was to control for potential effects of multiple variables
simultaneously by using multivariate logistic regression for all
variables with p,0.05 in the univariate models. However, based
on the few univariate significant associations identified and small
sample size, we did not conduct this analysis. Data was analyzed
with SAS software (version 9.1, SAS Institute, Cary, NC, USA).
Results
Characteristics of included studies
Our final sample was comprised of 61 published RCTs
(Figure 1). The characteristics of included articles by funding
Bias Thiazolidinedione Trials
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source are shown in Table 1. All trials reported glycemic control
results and 49 (80%) of trials reported lipid level results. Little
variability was found in peer review status or appropriate
medication dosing. Only 33 (54%) of the trials were drug-drug
comparison trials, while the rest were placebo-controlled trials. Of
the 33 drug-drug comparisons, 2 also had placebo arms. We did
not code these placebo arms and they are not included in our
results. Six of the 61 trials (9.8%) were non-inferiority designs.
Seventy-nine percent of trials had conclusions that favored the
glitazone or ‘‘test’’ drug, while 69% reported favorable glycemic
control results. Of the 13 trials with conclusions that did not favor
the test (glitazone) drug, 4 had glycemic control results favoring the
glitazone. Moreover, there were 13 trials where the results
reported for glycemic control were inconsistent with the
conclusions of the papers [29–41]. Specifically, in 9 trials,
favorable conclusions were reported yet glycemic control results
were either similar or unfavorable to the comparator [29–37],
though notably two trials were focused on lipid effects or
inflammatory markers [36,37]. In 4 trials, the conclusions stated
that the comparison drugs were equivalent, but the results
reported favorable glycemic control for the glitazone [38–41],
though one of these trials was focused on lipid effects and
inflammatory markers [41]. Funding source was not disclosed in
24 (39%) of the trials. Among trials with disclosed funding, 30
trials had some funding from a glitazone manufacturer and 26 of
these were funded exclusively by a glitazone manufacturer. Only 6
of the 37 trials, where funding source was disclosed, were funded
by comparator drug companies exclusively and only one of these
37 trials declared no drug company funding.
Association of trial characteristics with results or
conclusions that favor glitazones
Results of the univariate exact logistic regression analysis used to
identify associations between favorable results or conclusions and
explanatory variables are given in Tables 2 and 3 respectively.
Studies that report favorable glycemic control results were about 5
times more likely to be adequately blinded than not and four times
more likely to have a corresponding author with financial ties to
the glitazone manufacturer. Additionally, studies that reported
lipid level results favorable to the glitazone were about four times
more likely to be funded by a glitazone manufacturer than another
sponsor (Table 2). Studies that reported conclusions favoring the
glitazone were 0.03 times as likely to be funded by a comparator
drug company and 0.8 times as likely to be published in journals
with higher (better) impact factors (Table 3).
Discussion
We examined the association between study design character-
istics and the results and conclusions of randomized controlled
trials of the currently marketed thiazolidinediones, pioglitazone
and rosiglitazone, versus either placebo or comparator drug. Our
hypothesis was that results and conclusions of published trials
would be more likely to favor the study sponsor’s drug or that of
Figure 1. Flowchart for Manuscript selection/ and inclusion.
doi:10.1371/journal.pone.0005826.g001
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Table 1. Characteristics of included articles by Funding Source (n = 61).
Characteristic Funding Source
Total
Test Drug (Glitazone)
Company*
Other Drug
Company All Other
No Funding
Disclosure
N=61 N=30 N=6 N=1 N=24
N (%) N (%) N (%) N (%) N (%)
Journal Characteristics
Peer-reviewed 59 (97) 29 (97) 6 (100) 1(100) 23 (96)
Impact factor N= 56**
IF, Quartiles**
Q1: ,= 2 14 (25) 7 (50) 0 (0) 1 (7) 6 (43)
Q2: 2.01–2.84 14 (25) 6 (43) 0 (0) 0 (0) 8 (57)
Q3: 2.85–5.75 14 (25) 8 (57) 2 (14) 0 (0) 4 (29)
Q4: .5.75 14 (25) 6 (43) 4 (29) 0 (0) 4 (29)
Study Characteristics
Comparison groups
Drug-Drug Comparison 33 (54) 17 (57) 5 (83) 0 (0) 11 (46)
Placebo Control Trial 28 (46) 13 (43) 1(17) 100 (1) 13 (54)
Sample size***
Sample size***, quartile
Q1: ,= 114 16 (26) 8 (50) 1 (6) 0 (0) 7 (44)
Q2: 115–252 15 (25) 6 (40) 3 (20) 1 (7) 5 (33)
Q3: 253–408 15 (25) 8 (53) 1 (7) 0 (0) 6 (40)
Q4: .408 15 (25) 8 (53) 1 (7) 0 (0) 6 (40)
Study design characteristics aimed at reducing bias
Adequate randomization & concealment of
allocation
15 (25) 9 (30) 1 (17) 0 (0) 5 (21)
Adequate blinding 36 (59) 18 (60) 2 (33) 0 (0) 15 (63)
Adequate intention to treat analysis 48 (79) 25 (83) 5 (83) 0 (0) 18 (75)
Adequate follow-up 48 (79) 23 (77) 5 (83) 1(100) 19 (79)
Appropriate medication dosing
Test drug (glitazone) n = 61 60 (98) 30 (100) 5 (83) 1 (100) 24 (100)
Comparator drug n = 33 30 (90) 16 (94) 5 (100) – 9 (82)
n = 17 n = 5 n= 0 n= 11
Results
Glycemic Control n = 61
Favorable to test drug (glitazone) 42 (69) 22 (73) 2 (33) 1 (100) 17 (71)
Lipid Level n = 49
Favorable to test drug 25 (51) 16 (70) 0 (0) 0 (0) 9 (45)
n = 23 n = 5 n= 1 n= 20
Conclusions n= 61
Favors test drug (glitazone) 48 (79) 26 (87) 1 (17) 1 (100) 20 (83)
Author characteristics
Corresponding author institutional affiliation
Test drug (glitazone) 16 (26) 11 (37) 0 (0) 0 (0) 5 (21)
Any other drug company 1 (2) 0 (0) 0 (0) 0 (0) 1 (4)
Academic/Hospital 43 (70) 19 (63) 6 (100) 1 (100) 17 (71)
All other/can’t determine 1 (2) 0 (0) 0 (0) 0 (0) 1 (4)
*Includes articles that were sponsored by glitazone company, another drug company and other non -drug company funding (n = 2) and by glitazone company and non-
drug-company (n = 2).
**Data from 5 articles were excluded because they were published in journals that had no impact factor. Of the N= 56 trials reported in journals with impact factors,
median value N=2.84, mean value = 4.63, range (0.34–44.02) and standard deviation s=6.06.
***Sample size characteristics, median value N= 252, mean value = 390, range (20–4360) and standard deviation s= 590.4.
doi:10.1371/journal.pone.0005826.t001
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Table 2. Association between characteristics of articles and statistically significant glycemic control and lipid level results that
favor the test drug: Univariate exact logistic regression.
Glycemic Control
Results
Odds Ratio
(95% CI) P value Lipid Level Results Odds Ratio (95% CI) P value
that favor test drug
(glitazone)
that favor test drug
(glitazone)
Favorable N/Total N (%) Favorable N/Total N (%)
Journal Characteristics
Journal Impact factor
Range 0.34–44.02 40/56 (71) 1.010 (0.912,
1.130)
0.8902 23/56 (41) 0.924 (0.742, 1.138) 0.4789
Mean Value = 4.63
Std deviation = 6.06
Median Value = 2.84
Study characteristics
Comparison Groups
Placebo Controlled trial 27/28 (96) 1.00 11/25 ( 44) 1.00
Drug–drug Comparative
trial
15/33 (46) 0.031 (0 , 0.245) 0 14/24 (58) 1.782 (0.499, 6.425) 0.4736
Sample size
Range 20–4360 42/61 1.002 (1.000,
1.005)
0.0394 25/49 0.999 (0.997, 1.001) 0.3720
Mean Value = 390
Std deviation = 590.4
Median Value = 252
Study design characteristics aimed at reducing bias
Randomization/Concealment of allocation
Adequate 11/15 (73) 1.331 (0.320,
6.669)
0.9292 5/10 (50) 0.950 (0.186, 4.868) 1.000
Blinding
Adequate 30/36 (83) 5.417 (1.459,
21.188)
0.0081 11/28 (39) 0.324 (0.083, 1.216) 0.1066
ITT Analysis
Adequate 36/48 (75) 4.200 (0.922,
19.750)
0.0664 18/38 (47) 0.514 (0.095, 2.464) 0.5453
Follow-up
Adequate 31/49 (63) 0.157 (0.003,
1.274)
0.1061 20/40 (50) 0.800 (0.138, 4.358) 1.0000
Appropriate Medication Dosing
Test drug – Adequate 42/60 (70) Infinite (0.057,
Infinite)
0.6230 25/48 (52) Infinite (0.027, Infinite) 0.9796
Comparator drug -
Adequate
14/30 (47) 1.750 (0.081,
110.507)
1.0000 12/21 (57) 0.667 (0.010, 14.997) 1.0000
Author characteristics
Corresponding Author Institutional Affiliation
Test drug company 16/16 (100) Infinite (0.410,
Infinite)
0.1176 8/13 (62) Infinite (0.034, Infinite) 0.8571
Any other industry 0/1 (0) – – 0/1 (0)
Academic/Hospital 26/43 (61) Infinite (0.037,
Infinite)
0.8182 17/35 (49) Infinite (0.023, Infinite) 1.0000
All Other 0/1 (0) 1.000 0/0 (0)
Funding information
Funding source
Test drug company/any
other industry/other drug
companies
0/2 (0) 0 (0, 1.656) 0.1111 2/2 (100) Infinite (0.092, Infinite) 0.8667
Bias Thiazolidinedione Trials
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the company with which an author had financial ties, and that
other design features would also be associated with results or
conclusions that favor the study sponsor’s drug. Our study adds
more support to the body of literature demonstrating that
pharmaceutical industry sponsored studies comparing drug and
placebo are more likely to favor the drug [5–8] and that the
sponsor’s drug in a drug-drug comparison is more likely to be
favored [2,13]. Further, our finding suggests that favorable results
and conclusions are associated with the financial ties the
corresponding author has with the sponsor of the study. We also
found that less favorable results and conclusions were obtained
when the study sponsor was a competitor. This may explain why
well-designed comparisons of thiazolidinediones (glitazones) versus
other type 2 diabetes drugs sometimes have contradictory results
when executed by different investigators with financial ties to
different pharmaceutical sponsors.
Several plausible explanations exist for our finding of the strong
association between favorable outcomes and corresponding author
financial ties or funding source for the study. Publication bias or
the fact that statistically significant results are published more often
than non-statistically significant results, may explain this associa-
tion as we only examined published studies [4]. Moreover,
corresponding authors with financial ties to a sponsor may be less
likely to publish results that are unfavorable to the sponsor. We
also found that adequate blinding and larger sample size was
associated with favorable glycemic control results. Thus, these two
characteristics of good trial design may be related to the industry
sponsorship. Recent research has shown that specific study design
characteristics are not reliably associated with treatment effect
sizes across different studies and medical areas [42].
Journal characteristics may influence the results and conclusions
of articles as the quality of reporting can vary with the journal.
Glycemic Control
Results
Odds Ratio
(95% CI) P value Lipid Level Results Odds Ratio (95% CI) P value
that favor test drug
(glitazone)
that favor test drug
(glitazone)
Favorable N/Total N (%) Favorable N/Total N (%)
Test drug company
employee author/no formal
disclosure
1/2 (50) 0.238 (0.003,
22.399)
0.7778 2/2 (100) Infinite (0.092, Infinite) 0.8667
Any other drug company 2/6 (33) 0.119 (0.009,
1.190)
0.0769 0/5 (0) 0 (0, 0.886) 0.0373
No drug company 1/1 (100) Infinite (0.006,
Infinite)
1.0000 0/1 (0) 0 (0, 26.000) 0.8000
No funding disclosure 17/24 (71) 0.578 (0.122,
2.590)
0.6238 9/20 (45) 0.477 (0.109, 2.043) 0.4153
Test drug funding
Test drug funding 22/30 (73) 1.512 (0.445,
5.269)
0.6416 16/23 (70) 4.317 (1.126, 17.134) 0.0300
Corresponding Author Financial Ties
Test drug company ties/any
other industry ties
2/5 (40) 0.133 (0.002,
3.502)
0.3939 2/3 (67) 2.000 (0.061, 156.747) 1.0000
Test drug company
employee/no formal
disclosure of ties
15/15 (100) Infinite (0.064,
Infinite)
0.5714 8/12 (67) 2.000 (0.173, 22.393) 0.8552
Any other industry ties 2/2 (100) Infinite (0.009,
Infinite)
1.0000 1/2 (50) 1.000 (0.010, 104.374) 1.0000
No disclosure of ties 18/32 (56) 0.257 (0.005,
2.776)
0.4388 10/25 (40) 0.667 (0.074, 6.103) 0.9987
Corresponding Author Test Drug Financial Ties
Test drug financial ties 22/26 (85) 4.125 (1.048,
19.525)
0.0409 13/21 (62) 2.167 (0.592, 8.099) 0.3025
First Author Financial Ties
Test drug company ties/any
other industry ties
2/5 (40) 0 (0, 2.027) 0.1667 2/3 (67) 1.333 (0.036, 117.498) 1.0000
Test drug company
employee/no formal
disclosure of ties
5/5 (100) 1.00 3/5 (60) 1.000 (0.042, 23.663) 1.0000
Any other industry ties 2/2 (100) 1.00 1/2 (50) 0.667 (0.006, 78.249) 1.0000
No disclosure of ties 28/44 (64) 0 (0, 2.188) 0.2489 16/34 (47) 0.593 (0.045, 5.955) 0.9492
First Author Test Drug Financial Ties
Test drug financial ties 12/15 (80) 2.133 ((0.469,
13.331)
0.4588 8/13 (62) 1.788 (0.414, 8.297) 0.5762
doi:10.1371/journal.pone.0005826.t002
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Table 3. Association between characteristics of articles and statistically significant author’s conclusions that favor the test drug:
Univariate exact logistic regression.
Conclusions that favor test drug
(glitazone) Odds Ratio (95% CI) P value
Favorable N/Total N (%)
Journal characteristics
Journal Impact factor
Range 0.34–44.02 45/56 (80) 0.794 (0.619, 0.967) 0.0109
Mean Value = 4.63
Std deviation = 6.06
Median Value = 2.84
Study characteristics
Comparison Groups
Placebo Controlled trial 25/28 (89) 1.00
Drug–drug Comparative trial 23/33 (70) 0.276 (0.044, 1.277) 0.1178
Sample size
Range 20–4360 48/61 (79) 1.000 (0.999, 1.001) 0.4099
Mean Value = 390
Std deviation = 590.4
Median Value = 252
Study design characteristics aimed at reducing bias
Randomization/Concealment of allocation
Adequate 13/15 (87) 2.043 (0.362, 21.213) 0.6354
Blinding
Adequate 31/36 (86) 2.918 (0.698, 13.026) 0.1689
ITT Analysis
Adequate 39/48 (81) 1.445 (0.208, 7.501) 0.8959
Follow-up
Adequate 38/49 (78) 0.691 (0.065, 4.051) 1.0000
Appropriate Medication Dosing
Test drug – Adequate 48/60 (80) Infinite (0.095, Infinite) 0.4262
Comparator drug - Adequate 20/30 (67) 0 (0, 5.654) 0.6492
Author characteristics
Corresponding Author Institutional
Affiliation
Test drug company 15/16 (94) Infinite (0.192, Infinite) 0.2353
Any other industry 0/1 (0) – –
Academic/Hospital 33/43 (77) Infinite (0.077, Infinite) 0.5000
All Other 0/1 (0) 1.000 –
Funding information
Funding source
Test drug company/any other industry/other
drug companies
1/2 (50) 0.130 (0.002, 13.627) 0.5397
Test drug company employee author/no formal
disclosure
2/2 (100) Infinite (0.020, Infinite) 1.0000
Any other drug company 1/6 ((17) 0.026 (0, 0.400) 0.0030
No drug company 1/1 (100) Infinite (0.003, Infinite) 1.0000
No funding disclosure 20/24 (83) 0.652 (0.086, 4.407) 0.9068
Test drug funding
Test drug funding 26/30 (87) 2.659 (0.623, 13.280) 0.2357
Corresponding Author Financial Ties
Test drug company ties/any other industry ties 2/5 (40) 0 (0, 1.644) 0.1212
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Articles published in peer-reviewed journals have superior quality
compared to articles published in non-peer reviewed journals [7].
In our sample there was no variability in peer review status.
However, we did find a significant association between favorable
conclusions and journal impact factor. Articles published in higher
impact journals were less likely to reach favorable conclusions than
articles published in journals with lower impact factors.
Our study had several limitations. Although we conducted a
comprehensive search, we identified only 61 trials for inclusion.
Our intention was to control for potential effects of multiple
variables simultaneously by using multivariate logistic regression
for all variables with p,0.05 in the univariate models. However,
based on the few univariate significant associations identified and
our small sample size, it was inappropriate to conduct this analysis.
Furthermore, due to the few significant associations detected, we
did not correct p-values in the univariate analysis for multiple
statistical tests. Second, we searched PubMed and the Cochrane
Library, but not other databases, such as Embase, so we may have
missed some published manuscripts relevant to our study. Third,
we categorized studies as funded by industry based on each
article’s disclosure and a large percentage (39%) of studies in our
sample had no disclosed funding sources. This lack of disclosure
could underestimate the number of industry sponsored studies and
personal ties of investigators [43]. Additionally, our study only
included randomized controlled trials and no observational
studies, and did not include any head-to-head comparisons of
one glitazone to another. Consequently, we cannot assess whether
or not one glitazone is favored over the other.
We found that the published trials are dominated by industry
sponsored studies. There is increasing concern that funding source
influences outcomes and conclusions of medical research. Over the
last few decades the amount of industry funded medical research has
increased dramatically and consequently could affect the balance of
published trials towards studies that favor new drugs over older
generic drugs [44,45]. More diversity in glitazone trial funding seems
warranted. Moreover, we found a very large percentage of placebo-
controlled trials which are not appropriate comparisons for
determining the value of a glitazone as an add-on therapy for
treating type 2 diabetes. We also found few head-to-head
comparisons of drug regimens containing glitazones versus drug
regimens containing insulin, which leaves clinicians unable to
evaluate the effectiveness of one combination regimen over another.
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